CD83 and neoplasm: To examine the expression of CD83 in tumor-infiltrating CAR-T cells compared with T cells outside the tumor, we administered anti-mesothelin CAR-T cells intratumorally into subcutaneous A375-mesothelin tumors and uncultured T cells from the same donor intravenously (Fig. 3a).